Roche Holding AG
ROG
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
E: investor.relations@roche.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,249
Roche Holding AG News & Analysis
personal-finance
The US dollar looks overvalued. Should individual investors care?
Some things are a lot more important to professional investors than everybody else.
stocks
3 cheap Wide Moat stocks in a divided industry
All but a couple of shares in this industry have sold off. Our analysts think these three high quality companies have fallen too far.
stocks
Obesity drug stocks: Where to invest now
Eli Lilly and Novo Nordisk have staged big rallies. Here’s how investors can approach this potentially huge opportunity.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,204.60 | 30.70 | 0.33% |
| CAC 40 | 8,200.88 | 15.70 | -0.19% |
| DAX 40 | 24,124.21 | 154.42 | -0.64% |
| Dow JONES (US) | 47,632.00 | 74.37 | -0.16% |
| FTSE 100 | 9,756.14 | 59.40 | 0.61% |
| HKSE | 26,482.22 | 136.08 | 0.52% |
| NASDAQ | 23,958.47 | 130.98 | 0.55% |
| Nikkei 225 | 51,271.60 | 36.05 | -0.07% |
| NZX 50 Index | 13,480.86 | 71.65 | 0.53% |
| S&P 500 | 6,890.59 | 0.30 | -0.00% |
| S&P/ASX 200 | 8,911.30 | 31.30 | 0.35% |
| SSE Composite Index | 4,010.23 | 6.10 | -0.15% |